# CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer

Source: https://onco.cc/trials/nct03568422/  
OnCo record `nct03568422` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of CFI-402257 run by Canadian Cancer Trials Group, active and no longer recruiting.

## Summary

CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer is a phase 1/2 interventional study registered as NCT03568422 by Canadian Cancer Trials Group, with 37 participants planned, started 2019-02-05. Conditions recorded: Breast Cancer. Interventions recorded: CFI-402257 and Paclitaxel.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03568422
- Phase: 1/2
- Setting: A Phase Ib and Open Label Phase II Study of CFI-402257 in Combination With Weekly Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer
- Sponsor: Canadian Cancer Trials Group
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT03568422: https://clinicaltrials.gov/study/NCT03568422

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- drugs: [CFI-402257](https://onco.cc/drugs/cfi-402257/)
- companies: [Treadwell Therapeutics](https://onco.cc/companies/treadwell-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct03568422.json